alessandra zingoni

Scopus Publications

Targeting RNA polymerase I to boost natural killer cell anticancer activity in multiple myeloma
Elena Sproviero, Eleonora Gnocchini, Tommaso Cipollone, Sara Petillo, Chiara Cassone, Rosa Molfetta, Alessandra Zingoni, Alessandra Soriani, Cristina Cerboni, Maria Teresa Petrucci, Francesca Fazio, Rossella Paolini, Gabriella Palmieri, Marco Cippitelli
Cell Death and Disease, 2025
Multiple myeloma (MM) remains an incurable disease despite therapeutic advancements extending survival. Relapses driven by drug resistance and minimal residual disease underscore the need for novel treatment strategies. Natural Killer (NK) cells play a key role in MM immunity, yet their function is suppressed by inhibitory cytokines and metabolites from the tumor microenvironment. Developing anticancer drugs with immunomodulatory properties, such as enhancing tumor sensitivity to NK cell recognition, remains a critical challenge. MM cells exhibit high protein synthesis rates, making them vulnerable to proteostasis disruption. Dysregulated ribosome function and aberrant mRNA translation contribute to proteasome inhibitor resistance. RNA Polymerase I (RNA Pol I)-mediated rDNA transcription, the rate-limiting step in ribosome biogenesis (RiBi), is significantly upregulated in MM. Targeting rDNA transcription and inducing nucleolar stress response (NSR) presents a promising therapeutic approach, though its immunomodulatory role is not well understood. Our study examined two “first-in-cla ss ” RNA Pol I inhibitors, CX-5461 and BMH-21, which differentially regulate NK cell-activating and inhibitory ligand expression in MM. BMH-21 enhanced NK cell degranulation and increased IFN-γ and TNF-α secretion, demonstrating stronger immunostimulatory effects than CX-5461. Conversely, CX-5461 induced a significant DNA damage response (DDR) and senescence, leading to HLA-E upregulation and suppressing NK cell activity. Mechanistic analyses revealed that HLA-E presentation is governed by ATR/AKT/mTORC1/S6K signaling and Pioneer Round of Translation (PRT), linking its regulation to DDR. This effect was modulated by Lenalidomide and Panobinostat. Moreover, RNA Pol I inhibition enhanced Daratumumab-mediated antibody-dependent cellular cytotoxicity (ADCC) of NK cells against MM, uncovering novel immuno-mediated antitumor mechanisms.
Precondensed Plasmid DNA Enhances CAR-T Cell Generation via Lipid Nanoparticles
Andrea Pirrottina, Serena Renzi, Luca Digiacomo, Francesca Giulimondi, Valentina De Lorenzi, Samuele Ghignoli, Luca Pesce, Francesco Cardarelli, Francesco Mura, Giacomo Parisi, Luca Buccini, Chiara Cassone, Alessandra Zingoni, Daniela Pozzi, Giulio Caracciolo
ACS Omega, 2025
The advent of chimeric antigen receptor (CAR) T-cell therapy has introduced a novel and personalized approach to cancer treatment. Despite its promise, the challenge of developing a system that bypasses the need for viral vectors remains significant, particularly in terms of achieving a clinical efficacy and sustained durability. To address these challenges, lipid nanoparticles (LNPs) produced through advanced microfluidic technology have been recently utilized to encapsulate plasmid DNA (pDNA) encoding CAR receptors. However, the intrinsic challenges associated with pDNA encapsulation, along with the critical requirement for efficient expression, remain substantial obstacles. Here, we show that incorporating DNA-condensing agents into the microfluidic manufacturing of LNPs effectively overcomes these limitations. Briefly, we conducted a preliminary investigation to characterize LNPs with and without the commercial condensing agent P3000-Reagent (PR), focusing on their physicochemical properties and scrutinizing the biological outcomes primarily in the HEK-293 cell line. Our results demonstrated that precondensation of the pDNA with PR differentially increased the transfection efficiency of the tested formulations, whereas confocal microscopy indicated reduced lysosomal colocalization and major nuclear localization. Finally, PR was found to enhance LNP efficiency upon multiple administrations to the immortalized T-lymphocyte Jurkat cell line, enabling the delivery of both a luciferase reporter gene and a functional CAR-encoding plasmid. Overall, these findings underscore the great potential of introducing DNA-condensing agents into the LNP preparation process, especially for systems designed for challenging delivery applications, such as multiadministration transfection protocols.
ADAR1 expression is associated with cervical cancer progression and negatively regulates NK cell activity
Valentina Tassinari, Marta Kaciulis, Stefano Petrai, Helena Stabile, Angelina Pernazza, Martina Leopizzi, Valeria Di Maio, Francesca Belleudi, Danilo Ranieri, Vanessa Mancini, Innocenza Palaia, Federica Tanzi, Ludovica Lospinoso Severini, Silvia Ruggeri, Maria Emanuela Greco, Giovanni Bernardini, Alessandra Zingoni, Marco Cippitelli, Cristina Cerboni, Alessandra Soriani
Jci Insight, 2025
ADAR1 edits double-stranded RNAs (dsRNAs) by deaminating adenosines into inosines, preventing aberrant activation of innate immunity by endogenous dsRNAs, which may resemble viral structures. Several tumors exploit ADAR1 to evade immune surveillance; indeed, its deletion reduces tumor viability and reshapes infiltrating leukocytes. Here we investigated the role of ADAR1 in immune evasion mechanisms during cervical cancer (CC) progression. Patients’ biopsy samples showed higher ADAR1 expression already in premalignant lesions (squamous intraepithelial lesions [SIL]) and a substantially reduced percentage of infiltrating CD7+ innate cells in in situ and invasive carcinomas compared with normal mucosa, with CD56+ NK cells showing phenotypic alterations that may have affected their functional responses. In CC-derived cell lines (SiHa, CaSki), ADAR1 silencing reduced cell proliferation, an effect further enhanced by exogenous IFN-β administration. It also induced proinflammatory gene expression, as demonstrated by RNA-Seq analysis, and conditioned supernatants collected from these cells activated several NK cell effector functions. NK cell infiltration and activation were also confirmed in organotypic 3D tissue models of SiHa cells knocked out for ADAR1. In conclusion, ADAR1 expression increased with CC progression and was accompanied by alterations in tumor-infiltrating NK cells, but its silencing in CC-derived cell lines potentiated antitumor NK cell activities. Thus, ADAR1 inhibition may represent a therapeutic perspective for CC and possibly other malignancies.
Protein-DNA Competition at the Bio-Nano Interface: Structural and Biological Insights From Graphene Oxide Coronas
Erica Quagliarini, Francesca Giulimondi, Serena Renzi, Andrea Pirrottina, Alessandra Zingoni, Nicholas Carboni, Daniela Pozzi, Giulio Caracciolo
Advanced Materials Interfaces, 2025
Understanding interactions between nanomaterials and biomolecules is essential for advancing biomedical nanotechnologies. This study investigates how double‐stranded DNA of varying sizes affects the protein corona (PC) surrounding Graphene Oxide (GO) nanosheets in DNA‐supplemented human plasma. The findings reveal that DNA plays a pivotal role in modulating the PC composition through dynamic competition governed by factors like surface charge, affinity, and DNA fragment size. At lower DNA concentrations, competition between DNA and proteins for binding sites on GO leads to a corona predominantly composed of proteins, with some DNA molecules also bound. However, as the DNA concentration increases beyond a threshold, a shift occurs. DNA increasingly outcompetes proteins for binding sites, resulting in a two‐component corona enriched with both DNA and proteins. Notably, the proportion of DNA within the corona progressively increases with rising DNA concentration, while the protein content decreases. This dynamic interplay between DNA and proteins has significant biological implications. A monotonic increase in Toll‐like receptor 9 (TLR9) activation is observed as the DNA content within the corona increases. As the corona composition and its influence on cellular responses are crucial, this study emphasizes the relevance of exploring competition at the bio‐nano interface for the advancement of these applications.
NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells
Caterina Marangio, Nadia Domenica Milito, Erisa Putro, Alessia Carnevale, Cristina Capuano, Alessandra Zingoni, Marco Cippitelli, Angela Santoni, Rossella Paolini, Rosa Molfetta
Frontiers in Immunology, 2025
IntroductionNatural Killer (NK) cells are cytotoxic innate lymphocytes able to detect transformed cells through the balanced action of inhibitory and activating receptors. NKG2D is one of the main activating receptors involved in tumor surveillance thanks to its ability to recognize stress-induced ligands. Of note, the prolonged exposure to NKG2D ligands promotes receptor down-modulation that results in defective activation of NKG2D and other unrelated activating receptors, including DNAM-1 that is also involved in tumor clearance. However, further investigations are necessary to characterize how the NKG2D/DNAM-1 interplay affects NK cell anti-tumor function.MethodsPrimary cultured human NK cells were stimulated with the natural ligand MICA or an anti-NKG2D agonist antibody. The expression of activating and inhibitory receptors as well as DNAM-1-triggered signaling events and cytotoxicity were evaluated by flow cytometry. DNAM-1-mediated granule polarization was evaluated by confocal microscopy.ResultsWe showed that NKG2D crosslinking mediated by the natural ligand MICA or an agonist antibody had different consequences on primary cultured human NK cells. Indeed, MICA stimulation increases the expression of the checkpoint receptor TIGIT that is able to counteract DNAM-1 activation. Stimulation with the agonist antibody, without altering TIGIT expression, directly inhibits DNAM-1-mediated signal transduction and cytotoxic function with a mechanism that required NKG2D endocytosis.DiscussionOur findings contribute to shed light on the functional consequences of NKG2D engagement, demonstrating that a direct impact on DNAM-1-mediated signal transduction occurs independently from the modality of NKG2D crosslinking. Understanding the molecular mechanisms responsible for suppression of NK cell activation may help the development of therapeutic anti-cancer strategies aimed to prevent NK cell dysfunction or to reinvigorate an impaired cytotoxic activity.
The senescence journey in cancer immunoediting
Alessandra Zingoni, Fabrizio Antonangeli, Silvano Sozzani, Angela Santoni, Marco Cippitelli, Alessandra Soriani
Molecular Cancer, 2024
Cancer progression is continuously controlled by the immune system which can identify and destroy nascent tumor cells or inhibit metastatic spreading. However, the immune system and its deregulated activity in the tumor microenvironment can also promote tumor progression favoring the outgrowth of cancers capable of escaping immune control, in a process termed cancer immunoediting. This process, which has been classified into three phases, i.e. “elimination”, “equilibrium” and “escape”, is influenced by several cancer- and microenvironment-dependent factors. Senescence is a cellular program primed by cells in response to different pathophysiological stimuli, which is based on long-lasting cell cycle arrest and the secretion of numerous bioactive and inflammatory molecules. Because of this, cellular senescence is a potent immunomodulatory factor promptly recruiting immune cells and actively promoting tissue remodeling. In the context of cancer, these functions can lead to both cancer immunosurveillance and immunosuppression. In this review, the authors will discuss the role of senescence in cancer immunoediting, highlighting its context- and timing-dependent effects on the different three phases, describing how senescent cells promote immune cell recruitment for cancer cell elimination or sustain tumor microenvironment inflammation for immune escape. A potential contribution of senescent cells in cancer dormancy, as a mechanism of therapy resistance and cancer relapse, will be discussed with the final objective to unravel the immunotherapeutic implications of senescence modulation in cancer.
Structuring lipid nanoparticles, DNA, and protein corona into stealth bionanoarchitectures for in vivo gene delivery
Serena Renzi, Luca Digiacomo, Daniela Pozzi, Erica Quagliarini, Elisabetta Vulpis, Maria Valeria Giuli, Angelica Mancusi, Bianca Natiello, Maria Gemma Pignataro, Gianluca Canettieri, Laura Di Magno, Luca Pesce, Valentina De Lorenzi, Samuele Ghignoli, Luisa Loconte, Carmela Maria Montone, Anna Laura Capriotti, Aldo Laganà, Carmine Nicoletti, Heinz Amenitsch, Marco Rossi, Francesco Mura, Giacomo Parisi, Francesco Cardarelli, Alessandra Zingoni, Saula Checquolo, Giulio Caracciolo
Nature Communications, 2024
Lipid nanoparticles (LNPs) play a crucial role in addressing genetic disorders, and cancer, and combating pandemics such as COVID-19 and its variants. Yet, the ability of LNPs to effectively encapsulate large-size DNA molecules remains elusive. This is a significant limitation, as the successful delivery of large-size DNA holds immense potential for gene therapy. To address this gap, the present study focuses on the design of PEGylated LNPs, incorporating large-sized DNA, departing from traditional RNA and ionizable lipids. The resultant LNPs demonstrate a unique particle morphology. These particles were further engineered with a DNA coating and plasma proteins. This multicomponent bionanoconstruct exhibits enhanced transfection efficiency and safety in controlled laboratory settings and improved immune system evasion in in vivo tests. These findings provide valuable insights for the design and development of bionanoarchitectures for large-size DNA delivery, opening new avenues for transformative gene therapies. Encapsulation of large-size DNA molecules into lipid nanoparticles (LNPs) remains challenging. Here, the authors engineer PEGylated LNPs with DNA and plasma proteins to improve the delivery of large DNA molecules, enhancing the gene therapy potential.
Optimizing Transfection Efficiency in CAR-T Cell Manufacturing through Multiple Administrations of Lipid-Based Nanoparticles
Francesca Giulimondi, Luca Digiacomo, Serena Renzi, Chiara Cassone, Andrea Pirrottina, Rosa Molfetta, Ilaria Elena Palamà, Gabriele Maiorano, Giuseppe Gigli, Heinz Amenitsch, Daniela Pozzi, Alessandra Zingoni, Giulio Caracciolo
ACS Applied Bio Materials, 2024
The existing manufacturing protocols for CAR-T cell therapies pose notable challenges, particularly in attaining a transient transfection that endures for a significant duration. To address this gap, this study aims to formulate a transfection protocol utilizing multiple lipid-based nanoparticles (LNPs) administrations to enhance transfection efficiency (TE) to clinically relevant levels. By systematically fine-tuning and optimizing our transfection protocol through a series of iterative refinements, we have accomplished a remarkable one-order-of-magnitude augmentation in TE within the immortalized T-lymphocyte Jurkat cell line. This enhancement has been consistently observed over 2 weeks, and importantly, it has been achieved without any detrimental impact on cell viability. In the subsequent phase of our study, we aimed to optimize the gene delivery system by evaluating three lipid-based formulations tailored for DNA encapsulation using our refined protocol. These formulations encompassed two LNPs constructed from ionizable lipids and featuring systematic variations in lipid composition (iLNPs) and a cationic lipoplex (cLNP). Our findings showcased a notable standout among the three formulations, with cLNP emerging as a frontrunner for further refinement and integration into the production pipeline of CAR-T therapies. Consequently, cLNP was scrutinized for its potential to deliver CAR-encoding plasmid DNA to the HEK-293 cell line. Confocal microscopy experiments demonstrated its efficiency, revealing substantial internalization compared to iLNPs. By employing a recently developed confocal image analysis method, we substantiated that cellular entry of cLNP predominantly occurs through macropinocytosis. This mechanism leads to heightened intracellular endosomal escape and mitigates lysosomal accumulation. The successful expression of anti-CD19-CD28-CD3z, a CAR engineered to target CD19, a protein often expressed on the surface of B cells, was confirmed using a fluorescence-based assay. Overall, our results indicated the effectiveness of cLNP in gene delivery and suggested the potential of multiple administration transfection as a practical approach for refining T-cell engineering protocols in CAR therapies. Future investigations may focus on refining outcomes by adjusting transfection parameters like nucleic acid concentration, lipid-to-DNA ratio, and incubation time to achieve improved TE and increased gene expression levels.
CD38 restrains the activity of extracellular cGAMP in a model of multiple myeloma
Lorenzo Cuollo, Samuele Di Cristofano, Annamaria Sandomenico, Emanuela Iaccarino, Angela Oliver, Alessandra Zingoni, Marco Cippitelli, Cinzia Fionda, Sara Petillo, Andrea Kosta, Valentina Tassinari, Maria Teresa Petrucci, Francesca Fazio, Menotti Ruvo, Angela Santoni, Domenico Raimondo, Alessandra Soriani
Iscience, 2024
molecular modeling and cell-free biochemical assays to show a direct interaction between the catalytic pocket of CD38 and cGAMP. Altogether, our findings expand the current knowledge about the regulation of cGAMP activity.
NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells
Sara Petillo, Elena Sproviero, Luisa Loconte, Lorenzo Cuollo, Alessandra Zingoni, Rosa Molfetta, Cinzia Fionda, Alessandra Soriani, Cristina Cerboni, Maria Teresa Petrucci, Francesca Fazio, Rossella Paolini, Angela Santoni, Marco Cippitelli
Cell Death and Disease, 2023
Natural Killer (NK) cells act as important regulators in the development and progression of hematological malignancies and their suppressor activity against Multiple Myeloma (MM) cells has been confirmed in many studies. Significant changes in the distribution of NK cell subsets and dysfunctions of NK cell effector activities were described in MM patients and correlated with disease staging. Thus, restoring or enhancing the functionality of these effectors for the treatment of MM represents a critical need. Neddylation is a post-translational modification that adds a ubiquitin-like molecule, NEDD8, to the substrate protein. One of the outcomes is the activation of the Cullin Ring Ligases (CRLs), a class of ubiquitin-ligases that controls the degradation of about 20% of proteasome-regulated proteins. Overactivation of CRLs has been described in cancer and can lead to tumor growth and progression. Thus, targeting neddylation represents an attractive approach for cancer treatment. Our group has recently described how pharmacologic inhibition of neddylation increases the expression of the NKG2D activating receptor ligands, MICA and MICB, in MM cells, making these cells more susceptible to NK cell degranulation and killing. Here, we extended our investigation to the direct role of neddylation on NK cell effector functions exerted against MM. We observed that inhibition of neddylation enhanced NK cell-mediated degranulation and killing against MM cells and improved Daratumumab/Elotuzumab-mediated response. Mechanistically, inhibition of neddylation increased the expression of Rac1 and RhoA GTPases in NK cells, critical mediators for an efficient degranulation at the immunological synapse of cytotoxic lymphocytes, and augmented the levels of F-actin and perforin polarization in NK cells contacting target cells. Moreover, inhibition of neddylation partially abrogated TGFβ-mediated repression of NK cell effector activity. This study describes the role of neddylation on NK cell effector functions and highlights the positive immunomodulatory effects achieved by the inhibition of this pathway in MM.
Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing
E. Vulpis, Luisa Loconte, Chiara Cassone, F. Antonangeli, G. Caracciolo, L. Masuelli, F. Fazio, Maria Teresa Petrucci, C. Fionda, A. Soriani, C. Cerboni, M. Cippitelli, A. Santoni, A. Zingoni
International Journal of Molecular Sciences, 2023
Doxorubicin–Mediated miR–433 Expression on Exosomes Promotes Bystander Senescence in Multiple Myeloma Cells in a DDR–Independent Manner
Elisabetta Vulpis, Lorenzo Cuollo, Cristiana Borrelli, Fabrizio Antonangeli, Laura Masuelli, Marco Cippitelli, Cinzia Fionda, Giulio Caracciolo, Maria Teresa Petrucci, Angela Santoni, Alessandra Zingoni, Alessandra Soriani
International Journal of Molecular Sciences, 2023
NKG2D engagement on human NK cells leads to DNAM-1 hypo-responsiveness through different converging mechanisms
Nadia D. Milito, Alessandra Zingoni, Helena Stabile, Alessandra Soriani, Cristina Capuano, Marco Cippitelli, Angela Gismondi, Angela Santoni, Rossella Paolini, Rosa Molfetta
European Journal of Immunology, 2023
Editorial: Women in NK and innate lymphoid cell biology
Alessandra Zingoni, Teresa Bellón
Frontiers in Immunology, 2023
Rescue SLAMF7 activity in exhausted natural killer cells: Novel challenges in the immunotherapy of multiple myeloma
Alessandra Zingoni, Marco Cippitelli
Clinical and Translational Discovery, 2022
GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells
Andrea Kosta, Abdelilah Mekhloufi, Lorenzo Lucantonio, Alessandra Zingoni, Alessandra Soriani, Marco Cippitelli, Angela Gismondi, Francesca Fazio, Maria Teresa Petrucci, Angela Santoni, Helena Stabile, Cinzia Fionda
Frontiers in Immunology, 2022
In vitro and ex vivo nano-enabled immunomodulation by the protein corona
Francesca Giulimondi, Luca Digiacomo, Elisabetta Vulpis, Luisa Loconte, Gianmarco Ferri, Francesco Cardarelli, Daniela Pozzi, Alessandra Zingoni, Giulio Caracciolo
Nanoscale, 2022
Large−Scale Profiling of Extracellular Vesicles Identified miR−625−5p as a Novel Biomarker of Immunotherapy Response in Advanced Non−Small−Cell Lung Cancer Patients
Francesco Pantano, Francesca Zalfa, Michele Iuliani, Sonia Simonetti, Paolo Manca, Andrea Napolitano, Simone Tiberi, Marco Russano, Fabrizio Citarella, Simone Foderaro, Elisabetta Vulpis, Alessandra Zingoni, Laura Masuelli, Roberto Bei, Giulia Ribelli, Marzia Del Re, Romano Danesi, Bruno Vincenzi, Giuseppe Perrone, Giuseppe Tonini, Daniele Santini
Cancers, 2022
PIGR-enriched circulating vesicles contributes to hepatocellular carcinoma aggressiveness
Alessandra Zingoni, Jesus M. Banales
Journal of Hepatology, 2022
When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer
M. S. Hasim, M. Marotel, Jonathan J. Hodgins, E. Vulpis, Olivia J Makinson, Sara Asif, Han-Yun Shih, Amit K Scheer, Olivia MacMillan, Felipe G Alonso, K. Burke, D. Cook, Rui Li, M. Petrucci, A. Santoni, P. Fallon, A. Sharpe, G. Sciumè, A. Veillette, A. Zingoni, D. Gray, A. McCurdy, M. Ardolino
Science Advances, 2022
Opsonin-Deficient Nucleoproteic Corona Endows UnPEGylated Liposomes with Stealth Properties In Vivo
Francesca Giulimondi, Elisabetta Vulpis, Luca Digiacomo, Maria Valeria Giuli, Angelica Mancusi, Anna Laura Capriotti, Aldo Laganà, Andrea Cerrato, Riccardo Zenezini Chiozzi, Carmine Nicoletti, Heinz Amenitsch, Francesco Cardarelli, Laura Masuelli, Roberto Bei, Isabella Screpanti, Daniela Pozzi, Alessandra Zingoni, Saula Checquolo, Giulio Caracciolo
ACS Nano, 2022
Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance
Elisabetta Vulpis, Luisa Loconte, Agnese Peri, Rosa Molfetta, Giulio Caracciolo, Laura Masuelli, Luana Tomaipitinca, Giovanna Peruzzi, Sara Petillo, Maria Teresa Petrucci, Francesca Fazio, Lucilla Simonelli, Cinzia Fionda, Alessandra Soriani, Cristina Cerboni, Marco Cippitelli, Rossella Paolini, Giovanni Bernardini, Gabriella Palmieri, Angela Santoni, Alessandra Zingoni
Journal of Extracellular Vesicles, 2022
Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation
Cinzia Fionda, Helena Stabile, Rosa Molfetta, Andrea Kosta, Giovanna Peruzzi, Silvia Ruggeri, Alessandra Zingoni, Cristina Capuano, Alessandra Soriani, Rossella Paolini, Angela Gismondi, Marco Cippitelli, Angela Santoni
European Journal of Immunology, 2021
Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition
Sara Petillo, Cristina Capuano, Rosa Molfetta, Cinzia Fionda, Abdelilah Mekhloufi, Chiara Pighi, Fabrizio Antonangeli, Alessandra Zingoni, Alessandra Soriani, Maria Teresa Petrucci, Ricciarda Galandrini, Rossella Paolini, Angela Santoni, Marco Cippitelli
Cell Death and Disease, 2021
The Possible Role of Sex As an Important Factor in Development and Administration of Lipid Nanomedicine-Based COVID-19 Vaccine
Elisabetta Vulpis, Francesca Giulimondi, Luca Digiacomo, Alessandra Zingoni, Reihaneh Safavi-Sohi, Shahriar Sharifi, Giulio Caracciolo, Morteza Mahmoudi
Molecular Pharmaceutics, 2021
Author Correction: Interplay of protein corona and immune cells controls blood residency of liposomes (Nature Communications, (2019), 10, 1, (3686), 10.1038/s41467-019-11642-7)
Francesca Giulimondi, Luca Digiacomo, Daniela Pozzi, Sara Palchetti, Elisabetta Vulpis, Anna Laura Capriotti, Riccardo Zenezini Chiozzi, Aldo Laganà, Heinz Amenitsch, Laura Masuelli, Giovanna Peruzzi, Morteza Mahmoudi, Isabella Screpanti, Alessandra Zingoni, Giulio Caracciolo
Nature Communications, 2020
Samhd1 phosphorylation and cytoplasmic relocalization after human cytomegalovirus infection limits its antiviral activity
Simone De Meo, Valentina Dell’Oste, Rosa Molfetta, Valentina Tassinari, Lavinia Vittoria Lotti, Simone Vespa, Benedetta Pignoloni, Daniela Angela Covino, Laura Fantuzzi, Roberta Bona, Alessandra Zingoni, Ilaria Nardone, Matteo Biolatti, Alessandra Coscia, Rossella Paolini, Monsef Benkirane, Fredrik Edfors, Tatyana Sandalova, Adnane Achour, John Hiscott, Santo Landolfo, Angela Santoni, Cristina Cerboni
Plos Pathogens, 2020
Impact of the protein corona on nanomaterial immune response and targeting ability
Luca Digiacomo, Daniela Pozzi, Sara Palchetti, Alessandra Zingoni, Giulio Caracciolo
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 2020
Immune complexes exposed on mast cell-derived nanovesicles amplify allergic inflammation
Rosa Molfetta, Mario Lecce, Linda Quatrini, Giulio Caracciolo, Luca Digiacomo, Laura Masuelli, Nadia Domenica Milito, Elisabetta Vulpis, Alessandra Zingoni, Ricciarda Galandrini, Angela Santoni, Rossella Paolini
Allergy European Journal of Allergy and Clinical Immunology, 2020
Tuning the Orchestra: HCMV vs. Innate Immunity
Valentina Dell’Oste, Matteo Biolatti, Ganna Galitska, Gloria Griffante, Francesca Gugliesi, Selina Pasquero, Alessandra Zingoni, Cristina Cerboni, Marco De Andrea
Frontiers in Microbiology, 2020
NKG2D Ligand Shedding in Response to Stress: Role of ADAM10
Alessandra Zingoni, Elisabetta Vulpis, Luisa Loconte, Angela Santoni
Frontiers in Immunology, 2020
Cancer extracellular vesicles as novel regulators of NK cell response
Alessandra Soriani, Elisabetta Vulpis, Lorenzo Cuollo, Angela Santoni, Alessandra Zingoni
Cytokine and Growth Factor Reviews, 2020
Bone marrow stromal cell-derived IL-8 upregulates pvr expression on multiple myeloma cells via NF-KB transcription factor
Abdelilah Mekhloufi, Andrea Kosta, Helena Stabile, Rosa Molfetta, Alessandra Zingoni, Alessandra Soriani, Marco Cippitelli, Rossella Paolini, Angela Gismondi, Maria Rosaria Ricciardi, Maria Teresa Petrucci, Laura Masuelli, Giulio Caracciolo, Sara Palchetti, Angela Santoni, Cinzia Fionda
Cancers, 2020
Interplay of protein corona and immune cells controls blood residency of liposomes
Francesca Giulimondi, Luca Digiacomo, Daniela Pozzi, Sara Palchetti, Elisabetta Vulpis, Anna Laura Capriotti, Riccardo Zenezini Chiozzi, Aldo Laganà, Heinz Amenitsch, Laura Masuelli, Giovanna Peruzzi, Morteza Mahmoudi, Isabella Screpanti, Alessandra Zingoni, Giulio Caracciolo
Nature Communications, 2019
An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation
Luciano Castiello, Alessandra Zevini, Elisabetta Vulpis, Michela Muscolini, Matteo Ferrari, Enrico Palermo, Giovanna Peruzzi, Christian Krapp, Martin Jakobsen, David Olagnier, Alessandra Zingoni, Angela Santoni, John Hiscott
Cancer Immunology Immunotherapy, 2019
Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms
Maria Teresa Bilotta, Maria Pia Abruzzese, Rosa Molfetta, Gianluca Scarno, Cinzia Fionda, Alessandra Zingoni, Alessandra Soriani, Tina Garofalo, Maria Teresa Petrucci, Maria Rosaria Ricciardi, Rossella Paolini, Angela Santoni, Marco Cippitelli
FASEB Journal, 2019
Senescent cells: Living or dying is a matter of NK cells
Fabrizio Antonangeli, Alessandra Zingoni, Alessandra Soriani, Angela Santoni
Journal of Leukocyte Biology, 2019
The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors
Maria Pia Abruzzese, Maria Teresa Bilotta, Cinzia Fionda, Alessandra Zingoni, Alessandra Soriani, Maria Teresa Petrucci, Maria Rosaria Ricciardi, Rosa Molfetta, Rossella Paolini, Angela Santoni, Marco Cippitelli
Cell Death and Disease, 2019
Cancer exosomes as conveyors of stress-induced molecules: New players in the modulation of NK cell response
Elisabetta Vulpis, Alessandra Soriani, Cristina Cerboni, Angela Santoni, Alessandra Zingoni
International Journal of Molecular Sciences, 2019
Post-translational mechanisms regulating nk cell activating receptors and their ligands in cancer: Potential targets for therapeutic intervention
Rosa Molfetta, Alessandra Zingoni, Angela Santoni, Rossella Paolini
Frontiers in Immunology, 2019
Key role of the CD56lowCD16low natural killer cell subset in the recognition and killing of multiple myeloma cells
Elisabetta Vulpis, Helena Stabile, Alessandra Soriani, Cinzia Fionda, Maria Petrucci, Elena Mariggio’, Maria Ricciardi, Marco Cippitelli, Angela Gismondi, Angela Santoni, Alessandra Zingoni
Cancers, 2018
Translating the anti-myeloma activity of Natural Killer cells into clinical application
Cinzia Fionda, Helena Stabile, Rosa Molfetta, Alessandra Soriani, Giovanni Bernardini, Alessandra Zingoni, Angela Gismondi, Rossella Paolini, Marco Cippitelli, Angela Santoni
Cancer Treatment Reviews, 2018
Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties
Laura Santangelo, Veronica Bordoni, Claudia Montaldo, Eleonora Cimini, Alessandra Zingoni, Cecilia Battistelli, Gianpiero D'Offizi, Maria R. Capobianchi, Angela Santoni, Marco Tripodi, Chiara Agrati
Liver International, 2018
Drug-induced senescent multiple myeloma cells elicit nk cell proliferation by direct or exosome-mediated IL15 trans-presentation
Cristiana Borrelli, Biancamaria Ricci, Elisabetta Vulpis, Cinzia Fionda, Maria Rosaria Ricciardi, Maria Teresa Petrucci, Laura Masuelli, Agnese Peri, Marco Cippitelli, Alessandra Zingoni, Angela Santoni, Alessandra Soriani
Cancer Immunology Research, 2018
Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7
Valentina Salvi, Veronica Gianello, Sara Busatto, Paolo Bergese, Laura Andreoli, Ugo D’Oro, Alessandra Zingoni, Angela Tincani, Silvano Sozzani, Daniela Bosisio
Jci Insight, 2018
MICA-129 dimorphism and soluble MICA are associated with the progression of multiple myeloma
Alessandra Zingoni, Elisabetta Vulpis, Francesca Cecere, Maria G. Amendola, Daniel Fuerst, Taron Saribekyan, Adnane Achour, Tatyana Sandalova, Ilaria Nardone, Agnese Peri, Alessandra Soriani, Cinzia Fionda, Elena Mariggiò, Maria T. Petrucci, Maria R. Ricciardi, Joannis Mytilineos, Marco Cippitelli, Cristina Cerboni, Angela Santoni
Frontiers in Immunology, 2018
NKG2D and its ligands: "One for all, all for one"
Alessandra Zingoni, Rosa Molfetta, Cinzia Fionda, Alessandra Soriani, Rossella Paolini, Marco Cippitelli, Cristina Cerboni, Angela Santoni
Frontiers in Immunology, 2018
High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma
Giovanni Bernardini, Elisabetta Vulpis, Valentina Bonanni, Helena Stabile, Maria Rosaria Ricciardi, Maria Teresa Petrucci, Angela Gismondi, Angela Santoni, Alessandra Zingoni
Leukemia and Lymphoma, 2017
Natural killer cell response to chemotherapy-stressed cancer cells: Role in tumor immunosurveillance
Alessandra Zingoni, Cinzia Fionda, Cristiana Borrelli, Marco Cippitelli, Angela Santoni, Alessandra Soriani
Frontiers in Immunology, 2017
Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis
Elisabetta Vulpis, Francesca Cecere, Rosa Molfetta, Alessandra Soriani, Cinzia Fionda, Giovanna Peruzzi, Giulio Caracciolo, Sara Palchetti, Laura Masuelli, Lucilla Simonelli, Ugo D'Oro, Maria Pia Abruzzese, Maria Teresa Petrucci, Maria Rosaria Ricciardi, Rossella Paolini, Marco Cippitelli, Angela Santoni, Alessandra Zingoni
Oncoimmunology, 2017
p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells
Alessandra Soriani, Cristiana Borrelli, Biancamaria Ricci, Rosa Molfetta, Alessandra Zingoni, Cinzia Fionda, Silvia Carnevale, Maria Pia Abruzzese, Maria Teresa Petrucci, Maria Rosaria Ricciardi, Giuseppe La Regina, Erica Di Cesare, Patrizia Lavia, Romano Silvestri, Rossella Paolini, Marco Cippitelli, Angela Santoni
Oncoimmunology, 2017
NK cell effector functions in a Chédiak-Higashi patient undergoing cord blood transplantation: Effects of in vitro treatment with IL-2
Loredana Cifaldi, Rita Maria Pinto, Ippolita Rana, Maurizio Caniglia, Adriano Angioni, Stefano Petrocchi, Caterina Cancrini, Laura Cursi, Giuseppe Palumbo, Alessandra Zingoni, Angela Gismondi, Paolo Rossi, Angela Santoni, Cristina Cerboni
Immunology Letters, 2016
Distinct roles for human cytomegalovirus immediate early proteins IE1 and IE2 in the transcriptional regulation of MICA and PVR/CD155 expression
Benedetta Pignoloni, Cinzia Fionda, Valentina Dell’Oste, Anna Luganini, Marco Cippitelli, Alessandra Zingoni, Santo Landolfo, Giorgio Gribaudo, Angela Santoni, Cristina Cerboni
Journal of Immunology, 2016
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: Role of cMYC-IRF4-miR-125b interplay
Maria Pia Abruzzese, Maria Teresa Bilotta, Cinzia Fionda, Alessandra Zingoni, Alessandra Soriani, Elisabetta Vulpis, Cristiana Borrelli, Beatrice Zitti, Maria Teresa Petrucci, Maria Rosaria Ricciardi, Rosa Molfetta, Rossella Paolini, Angela Santoni, Marco Cippitelli
Journal of Hematology and Oncology, 2016
Targeting NKG2D and NKp30 ligands shedding to improve NK cell–based immunotherapy
Alessandra Zingoni, Elisabetta Vulpis, Ilaria Nardone, Alessandra Soriani, Cinzia Fionda, Marco Cippitelli, Angela Santoni
Critical Reviews in Immunology, 2016
Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment
Andrea Ponzetta, Giorgia Benigni, Fabrizio Antonangeli, Giuseppe Sciumè, Emilio Sanseviero, Alessandra Zingoni, Maria Rosaria Ricciardi, Maria Teresa Petrucci, Angela Santoni, Giovanni Bernardini
Cancer Research, 2015
Genotoxic stress induces senescence-associated ADAM10-dependent release of NKG2D MIC ligands in multiple myeloma cells
Alessandra Zingoni, Francesca Cecere, Elisabetta Vulpis, Cinzia Fionda, Rosa Molfetta, Alessandra Soriani, Maria Teresa Petrucci, Maria Rosaria Ricciardi, Daniel Fuerst, Maria Giulia Amendola, Joannis Mytilineos, Cristina Cerboni, Rossella Paolini, Marco Cippitelli, Angela Santoni
Journal of Immunology, 2015
Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: Role of DNA damage response activation
Cinzia Fionda, Maria Pia Abruzzese, Alessandra Zingoni, Alessandra Soriani, Biancamaria Ricci, Rosa Molfetta, Rossella Paolini, Angela Santoni, Marco Cippitelli
BMC Cancer, 2015
NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma
Cinzia Fionda, Alessandra Soriani, Alessandra Zingoni, Angela Santoni, Marco Cippitelli
Biomed Research International, 2015
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
Cinzia Fionda, Maria Pia Abruzzese, Alessandra Zingoni, Francesca Cecere, Elisabetta Vulpis, Giovanna Peruzzi, Alessandra Soriani, Rosa Molfetta, Rossella Paolini, Maria Rosaria Ricciardi, Maria Teresa Petrucci, Angela Santoni, Marco Cippitelli
Oncotarget, 2015
Tumor-associated and immunochemotherapydependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients
M Christina Cox, Simone Battella, Raffaella La Scaleia, Sabrina Pelliccia, Arianna Di Napoli, Alessandra Porzia, Francesca Cecere, Eleonora Alma, Alessandra Zingoni, Fabrizio Mainiero, Luigi Ruco, Bruno Monarca, Angela Santoni, Gabriella Palmieri
Oncoimmunology, 2015
c-Cbl regulates MICA-but not ULBP2-induced NKG2D down-modulation in human NK cells
Rosa Molfetta, Linda Quatrini, Cristina Capuano, Francesca Gasparrini, Beatrice Zitti, Alessandra Zingoni, Ricciarda Galandrini, Angela Santoni, Rossella Paolini
European Journal of Immunology, 2014
The DNA damage response: A common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected, and cancer cells
Cristina Cerboni, Cinzia Fionda, Alessandra Soriani, Alessandra Zingoni, Margherita Doria, Marco Cippitelli, Angela Santoni
Frontiers in Immunology, 2014
Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: Role of STAT3
Cinzia Fionda, Giulia Malgarini, Alessandra Soriani, Alessandra Zingoni, Francesca Cecere, Maria Luisa Iannitto, Maria Rosaria Ricciardi, Vincenzo Federico, Maria Teresa Petrucci, Angela Santoni, Marco Cippitelli
Journal of Immunology, 2013
NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: Role in the NK cell-mediated negative regulation of T cell responses
Alessandra Zingoni, Michele Ardolino, Angela Santoni, Cristina Cerboni
Frontiers in Immunology, 2012
DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: Relevance for NK-T cell interaction
Michele Ardolino, Alessandra Zingoni, Cristina Cerboni, Francesca Cecere, Alessandra Soriani, Maria Luisa Iannitto, Angela Santoni
Blood, 2011
Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells
Elisa Lo Monaco, Elisa Tremante, Cristina Cerboni, Elisa Melucci, Leonardo Sibilio, Alessandra Zingoni, Maria Rita Nicotra, Pier Giorgio Natali, Patrizio Giacomini
Neoplasia, 2011
Modulation of T cell-mediated immune responses by natural killer cells
Alessandra Zingoni, Cristina Cerboni, Michele Ardolino, Angela Santoni
Natural Killer Cells at the Forefront of Modern Immunology, 2010
ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
Alessandra Soriani, Alessandra Zingoni, Cristina Cerboni, Maria Luisa Iannitto, Maria Rosaria Ricciardi, Valentina Di Gialleonardo, Marco Cippitelli, Cinzia Fionda, Maria Teresa Petrucci, Anna Guarini, Robin Foà, Angela Santoni
Blood, 2009
Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: Role of NKG2D ligands released by activated T cells
Cristina Cerboni, Michele Ardolino, Angela Santoni, Alessandra Zingoni
Blood, 2009
Natural killer (NK) cells from killers to regulators: Distinct features between peripheral blood and decidual NK cells
Angela Santoni, Alessandra Zingoni, Cristina Cerboni, Angela Gismondi
American Journal of Reproductive Immunology, 2007
Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis
Cristina Cerboni, Alessandra Zingoni, Marco Cippitelli, Mario Piccoli, Luigi Frati, Angela Santoni
Blood, 2007
Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity
Cristina Cerboni, Francesca Neri, Nicoletta Casartelli, Alessandra Zingoni, David Cosman, Paolo Rossi, Angela Santoni, Margherita Doria
Journal of General Virology, 2007
High-efficient lentiviral vector-mediated gene transfer into primary human NK cells
Federica Micucci, Alessandra Zingoni, Mario Piccoli, Luigi Frati, Angela Santoni, Ricciarda Galandrini
Experimental Hematology, 2006
Recognition of a carbohydrate xenoepitope by human NKRP1A (CD161)
Dale Christiansen, Effie Mouhtouris, Julie Milland, Alessandra Zingoni, Angela Santoni, Mauro S. Sandrin
Xenotransplantation, 2006
Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells
Lauren I Richie Ehrlich, Kouetsu Ogasawara, Jessica A Hamerman, Rayna Takaki, Alessandra Zingoni, James P Allison, Lewis L Lanier
Journal of Immunology, 2005
NK cell regulation of T cell-mediated responses
Alessandra Zingoni, Thierry Sornasse, Benjamin G. Cocks, Yuetsu Tanaka, Angela Santoni, Lewis L. Lanier
Molecular Immunology, 2005
Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions
Alessandra Zingoni, Thierry Sornasse, Benjamin G Cocks, Yuetsu Tanaka, Angela Santoni, Lewis L Lanier
Journal of Immunology, 2004
Src-dependent Syk activation controls CD69-mediated signaling and function on human NK cells
Simona Pisegna, Alessandra Zingoni, Gianluca Pirozzi, Benedetta Cinque, Maria Grazia Cifone, Stefania Morrone, Mario Piccoli, Luigi Frati, Gabriella Palmieri, Angela Santoni
Journal of Immunology, 2002
Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice
Stephen W. Chensue, Nicholas W. Lukacs, Tong-Yuan Yang, Xiaozhou Shang, Kirsten A. Frait, Steven L. Kunkel, Ted Kung, Maria T. Wiekowski, Joseph A. Hedrick, Donald N. Cook, Alessandra Zingoni, Satwant K. Narula, Albert Zlotnik, Franck J. Barrat, Anne O'Garra, Monica Napolitano, Sergio A. Lira
Journal of Experimental Medicine, 2001
CD69-triggered ERK activation and functions are negatively regulated by CD94/NKG2-A inhibitory receptor
Alessandra Zingoni, Gabriella Palmieri, Stefania Morrone, Marta Carretero, Miguel Lopez-Botel, Mario Piccoli, Luigi Frati, Angela Santoni
European Journal of Immunology, 2000
CD94/NKG2-A inhibitory complex blocks CD16-triggered Syk and extracellular regulated kinase activation, leading to cytotoxic function of human NK cells
Gabriella Palmieri, Valentino Tullio, Alessandra Zingoni, Mario Piccoli, Luigi Frati, Miguel Lopez-Botet, Angela Santoni
Journal of Immunology, 1999
Cutting edge: The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th2 cells
Alessandra Zingoni, Hortensia Soto, Joseph A Hedrick, Antonella Stoppacciaro, Clelia T Storlazzi, Francesco Sinigaglia, Daniele D’Ambrosio, Anne O’Garra, Douglas Robinson, Mariano Rocchi, Angela Santoni, Albert Zlotnik, Monica Napolitano
Journal of Immunology, 1998
Isolation and chromosomal localization of GPR31, a human gene encoding a putative G protein-coupled receptor
Alessandra Zingoni, Mariano Rocchi, Clelia Tiziana Storlazzi, Giovanni Bernardini, Angela Santoni, Monica Napolitano
Genomics, 1997
Molecular Cloning of TER1, a Chemokine Receptor-Like Gene Expressed by Lymphoid Tissues
Journal of Immunology, 1996
Molecular cloning and expression of cDNA encoding the rat UDP-N-acetylglucosamine:α-6-D-mannoside β-1,2-N-acetylglucosaminyltransferase II
Journal of Biological Chemistry, 1995

alessandra zingoni

RESEARCH INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS